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Abstract: Periconceptional  intake of folic acid is known to reduce a woman’s risk  of 
having  an  infant  affected  by  a  neural  tube  birth  defect  (NTD).  National  programs  to 
mandate  fortification  of  food  with  folic  acid  have  reduced  the  prevalence  of  NTDs 
worldwide. Uncertainty surrounding possible unintended consequences has led to concerns 
about higher folic acid intake and food fortification programs. This uncertainty emphasizes 
the need to continually monitor fortification programs for accurate measures of their effect 
and the ability to address concerns as they arise. This review highlights the history, effect, 
concerns, and future directions of folic acid food fortification programs. 
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1. History 
1.1. Folic Acid and the Prevention of Neural Tube Defects  
Folate is a water-soluble vitamin and includes endogenous food folate and its synthetic form, folic 
acid. In its naturally occurring form folate lacks stability in food storage and preparation [1]; however, 
folic acid is stable [1–3] and used for supplements and food fortification. There are many critical 
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cellular pathways dependent on folate as a one-carbon source, including DNA, RNA, and protein 
methylation, as well as DNA synthesis and maintenance [4]. A number of genetic polymorphisms 
affect  critical  components  of  folate  pathways  and  metabolism,  and  have  been  associated  with  an 
increased risk for NTDs [5]. However, the exact mechanism(s) by which folic acid reduces the risk of 
NTDs is not known and remains an active area of research. 
Neural  tube  defects  (NTDs)  occur  when  the  neural  tube  fails  to  close  early  in  embryonic 
development, resulting in damage to the exposed underlying neural tissue. These birth defects can result 
in significant morbidity and mortality depending on the location and severity of the lesion. The most 
severe―anencephaly―is incompatible with life; the lower lesions observed with spina bifida cause a 
range of morbidities, including urinary and fecal incontinence and paralysis of the lower limbs [6]. 
The relationship between apparent folate deficiency and NTD occurrence was hypothesized as early 
as 1965 [7]. After a number of studies suggested that folic acid might reduce the risk of NTDs [8–10], 
a randomized control trial (RCT) to determine the effectiveness of folic acid supplementation in the 
prevention of the recurrence of NTDs was undertaken by the British Medical Research Council [11]. 
That RCT found that women with a previous history of a pregnancy affected by an NTD reduced their 
recurrence risk by 70% by taking 4000 micrograms (µg ) of folic acid daily. The following year, in a 
Hungarian RCT, a 100% reduction in risk of a first occurrence of an NTD-affected pregnancy was 
found among women who took a prenatal vitamin containing 800 µg  of folic acid daily [12].  
In 1991, the Centers for Disease Control and Prevention recommended that women with a history 
of a prior NTD-affected pregnancy should consume 4000 µg  of folic acid daily starting at the time they 
begin planning a pregnancy [13]. Subsequently, in 1992, the U.S. Public Health Service recommended 
that  all  women  of  childbearing  age  consume  400  µg   of  folic  acid  daily  through  fortification, 
supplementation,  and  diet  to  prevent  NTDs  [14].  In  1998,  the  Institute  of  Medicine  (IOM) 
recommended that women capable of becoming pregnant should consume 400 µg  of folic acid daily 
from fortified foods or supplements, or both, in addition to that obtained through a normal diet [15]. 
In 2009, the U.S. Preventive Services Task Force published updated guidelines that reinforced these 
recommendations [16]. 
Encouraging women to consume a supplement containing 400 µg  of folic acid daily has limitations 
as  a  primary  public  health  program.  In  the  United  States,  up  to  50%  of  all  pregnancies  are 
unplanned [17]. The neural tube closes early in embryonic development (28 days after conception), 
therefore  a  woman  should  begin  folic  acid  supplementation  ideally  prior  to  becoming  pregnant. 
Education campaigns encouraging women to increase their use of supplements have not been effective 
at reaching every high-risk population [18]. To compound the problem, a recent UK cohort study 
showed that women planning a pregnancy only marginally increased their compliance with health 
behaviors and folic acid supplement use [19]. Other countries have recommendations to prevent NTDs 
by improving diet or encouraging supplement use, or both, but do not have mandatory fortification 
programs. An evaluation of NTD trends in such countries has revealed no significant changes since 
recommendations  were  enacted  [20].  It  has  been  suggested  that  well-implemented  mandatory 
fortification  programs,  unlike  voluntary  fortification  programs,  might  help  reduce  disparities  [21]. 
Given these issues, mandatory fortification programs have been implemented in many countries to 
maximize  their  effects  and  reduce  the  high  costs  associated  with  prevention  programs  such  as 
education campaigns and other interventions that require behavioral change [22].  Nutrients 2011, 3  
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1.2. Mandatory Food Fortification Programs 
Regulations for mandatory fortification of wheat flour with folic acid are currently in place in 
53 countries although in many cases these regulations have not been implemented [23]. In 2006, the 
World  Health  Organization  and  the  Food  and  Agricultural  Organization  of  the  United  Nations 
published guidelines to help countries to set the Target Fortification Level, the Minimum Fortification 
Level, the Maximum Fortification Level and the Legal Minimum Level of folic acid to be used to 
fortify flour with folic acid [24]. In the United States, mandatory fortification of enriched cereal grain 
products with folic acid was authorized in 1996 and fully implemented in 1998 [25]. The U.S. program 
adds 140 µg  of folic acid per 100 g of enriched cereal grain product and has been estimated to provide 
100–200 µg  of folic acid per day to women of childbearing age [26–28]. Although mandatory flour 
fortification programs increase folic acid intake, research has shown that they do not reach all women 
of reproductive age adequately [29,30]. For maximum benefit, folic acid fortification of additional 
food products might be needed to reach all population groups effectively [31]. The mandatory folic 
acid fortification level in select countries including the US is illustrated in Table 1 [32].  
Table 1. Levels of folic acid fortification in countries with mandatory fortification programs. 
Country  Fortification level   Date of implementation 
United States [25]  140 µ g/100 g  1998 
Canada [33]  150 µ g/100 g  1998 
Costa Rica [34]  180 µ g/100 g  1998 
Chile [35]  220 µ g/100 g  2000 
South Africa [36]  150 µ g/100 g  2003 
2. Effect of Mandatory Fortification of Food with Folic Acid on NTD Prevention 
2.1. NTDs 
The original impetus for folic acid food fortification programs was to reduce the occurrence of 
NTDs and associated morbidity and mortality, although a number of other health effects have been 
postulated. For the purposes of this review, we have limited this discussion to NTD risk reduction. 
Folic  acid  fortification  to  reduce  NTDs  is  considered  one  of  the  most  successful  public  health 
initiatives in the past 50–75 years [32]. Studies in the United States, using various methodologies, have 
shown decreases of 19%–32% in the prevalence of NTDs overall since the implementation of folic 
acid fortification in 1998 [37–40]. Larger decreases have been found in programs that were able to 
capture NTD cases using prenatal information, including elective terminations [37]. Recent reports 
have  suggested  that  anencephaly  and  spina  bifida  have  seen  similar  declines,  although  it  took 
additional years of fortification for the declines in anencephaly to match those of spina bifida [23,40]. 
Canada, South Africa, Costa Rica, Chile, Argentina, and Brazil also have reported declines in NTDs 
(19%–55%) since the initiation of folic acid food fortification [33–36,41–46]. The magnitude of the 
decrease in NTD prevalence observed in each country has been dependent on a number of factors. The 
greatest decline in NTD prevalence has been observed in those countries with the highest background 
prevalence. Other  variables that  have influenced the decline in NTD prevalence after fortification Nutrients 2011, 3  
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include  the  folate  status  of  the  population  before  fortification,  the  number  of  people  consuming 
fortified foods, and the ability of birth defects surveillance systems to effectively ascertain the decline 
in prevalence of NTDs as a result of folic acid fortification. Although there were variations in the rates 
of NTDs among countries before fortification (10.6–17.0 cases per 10,000 live births), since folic acid 
fortification the decreased rates have been less variable (6.3–10.0 cases per 10,000 live births), as 
previously reviewed [32]. These data suggest that a prevalence of 5–6 cases per 10,000 pregnancies 
represents the lowest prevalence that is achievable through current folic acid fortification practices and 
that  a  proportion  of  the  remaining  NTDs  are  not  sensitive  to  folic  acid  [23,32].  Recent  evidence 
indicates  that  low  maternal  vitamin  B12  is  a  significant  predictor  (independent  of  folate)  of  
NTD risk [47]. 
2.2. Blood Folate Concentrations and the Prevention of NTDs 
One  way  to  evaluate  the  effect  of  food  fortification  programs  is  to  measure  blood  folate 
concentrations among the population. Folate deficiency is defined as a serum folate concentration 
<7 nmol/L  (~3  ng/mL)  or  a  red  blood  cell  folate  concentration  <315  nmol/L  (~140  ng/mL)  [15]. 
Homocysteine concentration may be considered a ―functional‖ indicator of folate status in conjunction 
with blood folate concentrations [48]. Although the blood folate concentration needed to achieve a 
maximal reduction in the risk for folate-sensitive NTDs is unknown, among an Irish cohort, Daly et al. 
found that the greatest reduction in NTDs was observed at blood folate concentrations much higher 
than those set for folate deficiency [49]. This suggests that for NTD prevention elimination of folate 
deficiency is insufficient. Folic acid from multiple sources might be needed to achieve a blood folate 
concentration high enough for optimal NTD risk reduction [31].  
2.3. Higher Folic Acid Intake Relative to Sources 
In the United States, folic acid intake can come from multiple sources, including supplements, 
enriched cereal grain products, ready-to-eat breakfast cereals as well as other types of fortified food. 
A variety of foods can be fortified with folic acid under different U.S. Food and Drug Administration 
rules―such  as  ready-to-eat  breakfast  cereals  and  energy  bars  and  drinks―as  well  as  from  the 
mandatory fortification of enriched cereal grain products [50]. Supplements and ready-to-eat cereals 
provide up to 400 μg of folic acid in pill form or per serving, respectively.  
Since the implementation of mandatory folic acid fortification in the United States, the types of 
population-based studies examining the potential beneficial or adverse effects of such fortification 
have been limited. Available studies―such as cross-sectional, ecological, and case reports―cannot be 
used to establish causation. Most of the concern surrounding folic acid fortification comes from studies 
of higher intakes of folic acid or higher blood folate concentrations, or both. Pills used in RCTs testing 
the effectiveness of folic acid intake on other health outcomes commonly contain 800–2500 µg  of folic 
acid  [51],  and  higher  blood  folate  concentrations  are  associated  with  excess  use  of  supplements 
containing folic acid [50,52].  
The tolerable upper intake level (UL) (1000 μg/day) was established by the IOM in 1998 as one-fifth 
of the lowest observed adverse effect level (5000 μg/day) associated with a potential adverse outcome 
in  early  case  reports  (the  masking  of  vitamin  B12  deficiency  anemia)  [15].  Even  at  dosages  of  Nutrients 2011, 3  
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15,000–100,000 μg of folic acid daily, the IOM found limited evidence of direct toxicity from folic 
acid [53–58]. Recent studies have shed light on the means by which the intake would exceed the UL 
for most individuals. In a nationally representative study from the United States, Yang et al. found that 
food fortification supplied a steady low level of folic acid intake (~138 µg /day) and only 2.7% of the 
adult population had folic acid intakes that exceeded the UL [50]. Moreover, the only adults with usual 
intakes  above  the  UL  were  those  who  consumed  more  than  400  μg  of  folic  acid  daily  through 
supplements  [50,59].  Among  children  whose  usual  intake  of  folic  acid  was  limited  to  that  from 
enriched cereal grain products, no one’s usual intake exceeded the UL [60].  
3. Concerns about Potential Adverse Effects  
With  any  public  health  intervention,  there  are  concerns  about  potential  adverse  consequences. 
Continued monitoring of fortification programs is critical to be able to address emerging concerns as 
new hypotheses are generated. Monitoring could include regulatory oversight of the flour fortification 
industry, surveillance of NTDs if possible, surveys of blood folate concentrations in the population, 
and  surveillance  for  potential  adverse  effects.  Assessing  the  sources  and  amounts  of  folic  acid 
consumed is critical to studies because we know that fortification is a relatively small contributor to 
higher levels of daily folic acid intake. Folic acid has been used successfully for more than 40 years 
and throughout its use there have been concerns about its safety. In this review, we address some of the 
old and newly emerging concerns.  
3.1. Masking of B12 Deficiency Anemia 
Historically, concerns surrounding folic acid use have focused on the possibility that folic acid 
could mask the anemia caused by vitamin B12 deficiency. Early case reports (1940–1960) suggested 
≥5000 µg  of folic acid daily could mask a vitamin B12 deficiency by preventing the development of 
anemia. In turn, this could delay the diagnosis of an underlying vitamin B12 deficiency and thereby 
allow  vitamin  B12  deficiency-associated  neuropathies  to  progress  [15].  It  is  recognized  that  the 
diagnosis of a vitamin B12 deficiency and/or response to treatment should be dependent on a series of 
vitamin  B12  blood  status  indicators  and  not  solely  on  hematological  indices  which  may  not  be 
reliable [15].  The  IOM  concluded  in  1998  that  there  was  ―no  clear  evidence  of  folate-induced 
neurotoxicity in humans‖ [15]. Several studies both before and after fortification have examined this 
issue  and  concluded  that,  at  current  recommended  intakes,  there  is  little  evidence  of  masking  or 
exacerbation of neuropathies [61–64].  
3.2. Cancer and Epigenetic Changes 
Many  studies, as reviewed,  have  shown that a diet  high in folate (from fruits and  leafy green 
vegetables) is associated with lower risks of many types of cancer [65]. Recently, focus has shifted to 
the possibility that folic acid intake might lead to changes in epigenetic patterns. Epigenetics is the 
study  of  heritable  changes  that  do  not  involve  changes  in  DNA  sequence.  Folate  is  used  by  two 
different metabolic pathways―DNA synthesis and DNA methylation (an epigenetic modification)―as 
a source of one-carbon methyl groups [4]. Epigenetics has been hypothesized to play a key role at  Nutrients 2011, 3  
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the interface of gene–environment interactions and might help to explain different health outcomes  
(e.g.,  birth  defects,  cancer,  and  mental  health)  occurring  among  those  with  similar  genetic 
backgrounds [66–68].  
As a result of the fact that folate is a source of the methyl group for DNA methylation and that 
DNA methylation is a ubiquitous regulator, there are countless biologically plausible hypotheses of 
how folic acid might affect any disease of interest, either positively or negatively. Most of the concern 
has surrounded cancer, most likely because the field of epigenetics has been studied largely in the 
context of tumorogenesis [69–74]. There are clear DNA methylation pattern changes in tumors [73–75]. 
It has been suggested in a recent review that folic acid might prevent some cancers and might promote 
other neoplasias [76]. It has been hypothesized that early exposure to folic acid might prevent tumors 
through the provision of enough methyl groups to maintain proper methylation patterns and repair of 
DNA. In contrast, after the development of tumors, higher intake of folic acid might promote growth 
of existing tumors [76]. However, a very recent meta-analysis of the RCTs of the effects of B vitamins 
on  37,485  individuals  with  existing  cardiovascular  disease  showed  no  increased  risk  of  cancer 
incidence  (relative  risk  (RR)  1.05,  95%  confidence  interval  (CI)  0.98–1.13),  cancer  mortality 
(RR 1.00, 95% CI 0.85–1.18) or all-cause mortality (RR 1.02, 95% CI 0.97–1.08) [51]. Since the 
implementation of mandatory folic acid fortification in the United States in 1998, both incidence and 
mortality of colorectal cancer have continued to decline [77].  
In  2008,  the  European  Food  Safety  Authority  (EFSA)  convened  a  working  group  to  consider 
whether there was enough evidence to recommend a full risk assessment to determine whether folic 
acid was causing cancer, especially colorectal cancer. The EFSA concluded that, ―there are currently 
insufficient data to justify such an assessment and that current evidence does not show an association 
between high folic acid intakes and cancer risk but neither do they confidently exclude a risk‖ [78]. 
There are a number of knowledge gaps that need to be filled before we know if folic acid affects 
disease risk through DNA methylation in humans. The ―normal‖ patterns of DNA methylation across 
the genome are unknown, as are the ―normal‖ levels of variation among and between individuals and 
populations. The National Institutes of Health has an initiative to map the epigenome that is modeled 
on the Genome Project to begin to describe DNA methylation. It also is unknown if DNA methylation 
patterns among humans can be altered by folic acid or other micronutrients, or both, or if the patterns 
change by the timing of exposure (e.g., different response among adults vs. among children or fetuses). 
Animal models have shown that it is possible to alter the prenatal exposures to one-carbon sources 
(folic acid, choline, betaine, etc.) and affect DNA methylation at a specific locus and that this can 
affect the phenotype of the offspring regardless of the adult animal’s diet [79]. Currently, there is no 
evidence of this effect among humans. The interaction of folic acid and epigenetics will continue to 
produce hypotheses that will need to be tested carefully.  
3.3. Unmetabolized Folic Acid  
Folic acid normally is reduced to tetrahydrofolate following uptake by the liver [80]. If the body’s 
ability to reduce folic acid is exceeded, unmetabolized folic acid will be found circulating in the blood. 
One experimental study suggested that unmetabolized folic acid would be found after consuming a 
bolus of >200 μg of folic acid [81]. Intakes exceeding this threshold would be common through the use Nutrients 2011, 3  
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of supplements or fortified foods such as breakfast cereals [82], but unlikely would be reached through 
intake of folic acid from mandatory U.S. fortification levels alone [81,83–87]. Because folic acid has 
been a long-standing component of over-the-counter supplements and prenatal vitamins, if looked for, 
unmetabolized folic acid would have been found among a large proportion of the U.S. population for 
decades. Only recently has the laboratory equipment needed to measure circulating unmetabolized 
folic  acid  become  available.  Unmetabolized  folic  acid  has  been  found  among  many  groups 
examined―from older U.S. adults [87] to the cord blood from newly delivered infants [88]. It has 
been hypothesized that unmetabolized folic acid is related to cognitive impairment among seniors [89], 
although the findings might have been confounded by patients with pernicious anemia. Currently, there 
are no definitive studies that have found health effects from exposure to unmetabolized folic acid. 
4. Systematic Reviews of Potential Beneficial and Adverse Effects Prior to the Implementation of 
Folic Acid Fortification Programs 
The food safety agencies in a number of countries considering mandatory folic acid fortification 
have considered the potential that folic acid may have both beneficial and adverse effects. Among 
these agencies are the UK Food Standards Agency (FSA) [90], the Food Safety Authority of Ireland 
(FSAI) [91], Food Standards Australia New Zealand (FSANZ) [92], and the Health Council of the 
Netherlands  [93].  The  recommendation  to  approve  folic  acid  fortification  has  been  the  consensus 
decision presented in final reports from these countries. However, for a variety of reasons, to date only 
Australia has completed implementation of its program. 
4.1. Experiences in the United Kingdom 
In 2006, the Scientific Advisory Committee on Nutrition (SACN) of the UK FSA recommended 
that mandatory fortification with folic acid should proceed, together with controls on the intake of folic 
acid from voluntarily fortified foods [90]. Then in 2007, the SACN was convened at the request of the 
UK FSA to review potential adverse effects of folic acid on colorectal cancer risk because of two 
papers published earlier that year. In 2009, after an extensive review, the panel concluded that there 
currently were insufficient data to support the concerns that folic acid fortification promoted cancer 
and  announced  its  decision  to  support  its  previous  recommendation  for  mandatory  folic  acid 
fortification [94]. 
4.2. Experiences in Ireland 
In 2006, the FSAI recommended that mandatory fortification with 120 µg  of folic acid per 100 g of 
bread should begin without changing the existing practice of voluntarily fortifying foods with folic 
acid [91–95]. However, in 2008, the FSAI implementation group reported to the Department of Health 
and Children that mean intake of folate in Ireland had increased to 90 µg  daily, primarily from the 
intake  of  folic  acid  from  voluntarily  fortified  foods,  of  which  the  FSAI  documented  more  than 
200 individual  kinds  of  foods  [96].  In  2009,  the  FSAI  announced  that  because  (1)  women  of 
childbearing age were receiving 30% more folate in their diet than they were 3 years earlier (the source 
of which was mostly from voluntary fortification) and (2) the incidence of NTDs in Ireland had been Nutrients 2011, 3  
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reduced  to  9.3  per  10,000  livebirths,  there  would  be  limited  benefit  to  public  health  to  require 
mandatory folic acid fortification at that time [97]. This decision will be open to reconsideration as 
additional information becomes available on potential adverse outcomes [97]. Additionally, because 
previous studies have shown that voluntary fortification likely does not reach all subpopulations of 
women  of  childbearing  age  who  are  at  risk  [21]  and  given  that  NTD  prevalences  of  5–6  per 
10,000 livebirths have been achieved among other populations [98], there might be room for further 
reductions in folic acid-preventable NTDs in Ireland. 
4.3. Experiences in New Zealand and Australia 
In 2007, FSANZ recommended that Australia and New Zealand implement mandatory programs to 
fortify bread with folic acid. Both governments agreed to implement this plan by September 2009 [92]. 
However, in June 2009, bakers in New Zealand began a campaign to stop the plan [99]. The media 
campaign funded by the Baking Industry Association of New Zealand raised many concerns in the 
public’s mind as to the safety of folic acid fortification. As a result, the plan for mandatory fortification 
of  bread  in  New  Zealand  was  put  on  hold  for  3  years  [100];  Australia,  however,  implemented 
mandatory fortification as scheduled in September 2009. 
5. Future  
Existing  folic  acid  food  fortification  programs  have  reduced  significantly  the  number  of 
pregnancies  affected  by  NTDs  and  the  associated  morbidity  and  mortality.  In  the  future,  new 
hypotheses  will  be  generated  that  will  need  exploration  and  testing,  such  as  concerns  over  the 
possibility of epigenetic changes. Careful monitoring of existing and proposed programs will enable 
the scientific community to evaluate blood folate concentrations needed for NTD prevention, evaluate 
and respond appropriately to concerns as they arise, and document the benefit of these public health 
programs. As with any public health program, it is important to revisit recommendations regularly as 
additional  information  becomes  available.  A  significant  portion  of  the  estimated  300,000  NTDs 
worldwide that occur yearly are preventable by the consumption of folic acid and continue to be a 
great public health burden globally [32]. 
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